BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:HPV vaccines – will they do their job? - Professor Margaret Stan
 ley\, Dept of Pathology\, University of Cambridge
DTSTART:20091014T113000Z
DTEND:20091014T123000Z
UID:TALK19934@talks.cam.ac.uk
CONTACT:Prof. Jim Kaufman
DESCRIPTION:Viral infections cause at least 15% of all cancers\; one of th
 e most important oncogenic viruses is the human papillomavirus (HPV) a cau
 sal agent in 4% of all cancers.  The identification of the major oncogenic
  HPV’s HPV 16 and HPV 18 by Harald zur Hausen was recognised in 2008 by 
 the award to him of the Nobel Prize in Medicine.  The unfolding of the HPV
  story started in the 1970’s and has resulted in the development of prop
 hylactic vaccines using sophisticated recombinant molecular techniques and
  protein expression to prevent infection by HPV 16 and 18.  These vaccines
  are now licensed world wide and have been incorporated into national immu
 nisation programmes in several countries. The vaccines are remarkably effi
 cacious\, generate strong immunity and have a very good safety profile. Pr
 oviding these vaccines are delivered as part of an organised immunisation 
 programme and achieve high coverage they should significantly reduce the i
 ncidence of cervix cancer\, and other HPV associated cancers\, in the vacc
 inated cohort over the medium to long term.  However since the current vac
 cines provide protection only against the 2 major oncogenic HPVs 16 and 18
  that cause 70-80% of cervix cancers\, complete protection against HPV cau
 sed cervical cancer will require polyvalent vaccines or broadly protective
  products in the future.  Recent data on the mechanism of viral entry and 
 the dynamics of the interaction of the viral capsid proteins L1 and L2 wit
 h the cell surface provide a rationale for the design of second generation
  vaccines.
LOCATION:Lecture Theatre\, Department of Pathology\, Tennis Court Road
END:VEVENT
END:VCALENDAR